Frontino et al. (28) provided the first preliminary report on the use of daily liraglutide (GLP1-RA) for 8–27 months and demonstrated its safety, tolerability, and efficacy in four pediatric WS patients aged 10–14 years. Here, GLP1R is linked to Werner syndrome.